Kohei shitara (@KoheiShitara) / X

Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert

Oncology Data Advisor - Zolbetuximab: Gastric/Gastroesophageal Junction Adenocarcinoma

Kohei shitara (@KoheiShitara) / X

Jeroen Dekervel (@JDekervel) / X

Kohei Shitara, Videos & Research

Margherita Ambrosini (@margheambro1) / X

Raghav Sundar (@sundar__raghav) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Kohei shitara (@KoheiShitara) / X

Ryan Moy (@RyanMoyMDPhD) / X

Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology

Angelica Petrillo (@AngelicaSSophie) / X

Raghav Sundar (@sundar__raghav) / X

WCGIC 2023